This acquired resistance has been reported in different types of cancer (e.g., non-small-cell lung cancer [10,11]) and for different targets (e.g., hormonal therapy in estrogen receptor-positive breast cancer [12] or receptor tyrosine kinases [13,14]). Here, ESR1 is linked to cancer.